{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:56:07Z","timestamp":1792691767038,"version":"4.5.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013088","name":"Qinglan Project of Jiangsu Province of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013088","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","award":["BK20231482"],"award-info":[{"award-number":["BK20231482"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.drudis.2026.104728","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:05:08Z","timestamp":1782975908000},"page":"104728","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["From biologics to small-molecule modulators: the evolving landscape of interleukin-targeted therapeutics"],"prefix":"10.1016","volume":"31","author":[{"given":"Yiping","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qindi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0169-349X","authenticated-orcid":false,"given":"Shuai","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104728_b0005","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1084\/jem.139.6.1369","article-title":"Demonstration and characterization of two distinct human leukocytic pyrogens","volume":"139","author":"Dinarello","year":"1974","journal-title":"J Exp Med"},{"key":"10.1016\/j.drudis.2026.104728_b0010","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1002\/eji.200737772","article-title":"Historical insights into cytokines","volume":"37","author":"Dinarello","year":"2007","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.drudis.2026.104728_b0015","article-title":"Engineering strategies for immunomodulatory cytokine therapies: challenges and clinical progress","volume":"4","author":"Pires","year":"2021","journal-title":"Adv Ther (Weinh)"},{"key":"10.1016\/j.drudis.2026.104728_b0020","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1073\/pnas.252756299","article-title":"Binding of small molecules to an adaptive protein-protein interface","volume":"100","author":"Arkin","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2026.104728_b0025","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.4049\/jimmunol.167.3.1440","article-title":"Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2","volume":"167","author":"Debets","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2026.104728_b0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1600-065X.1986.tb01492.x","article-title":"The human interleukin-2 receptor: analysis of structure and function","volume":"92","author":"Greene","year":"1986","journal-title":"Immunol Rev"},{"key":"10.1016\/j.drudis.2026.104728_b0035","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nri2094","article-title":"Cytokines in the pathogenesis of rheumatoid arthritis","volume":"7","author":"McInnes","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drudis.2026.104728_b0040","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2026.104728_b0045","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41423-025-01358-8","article-title":"IL-1 family cytokines in inflammation and immunity","volume":"22","author":"Garlanda","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.drudis.2026.104728_b0050","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"Boyman","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drudis.2026.104728_b0055","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","article-title":"Targeting IL-6 trans-signalling: past, present and future prospects","volume":"23","author":"Rose-John","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drudis.2026.104728_b0060","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41586-020-2492-5","article-title":"Structural basis of CXC chemokine receptor 2 activation and signalling","volume":"585","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104728_b0065","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/ncomms2880","article-title":"Crystal structures of interleukin 17A and its complex with IL-17 receptor A","volume":"4","author":"Liu","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104728_b0070","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nm.3895","article-title":"IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases","volume":"21","author":"Teng","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2026.104728_b0075","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.smim.2014.01.009","article-title":"A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy","volume":"26","author":"Tanaka","year":"2014","journal-title":"Semin Immunol"},{"key":"10.1016\/j.drudis.2026.104728_b0080","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd3229","article-title":"Development trends for human monoclonal antibody therapeutics","volume":"9","author":"Nelson","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104728_b0085","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104728_b0090","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104728_b0095","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc1913","article-title":"Comparing antibody and small-molecule therapies for cancer","volume":"6","author":"Imai","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.drudis.2026.104728_b0100","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2026.104728_b0105","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104728_b0110","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/mt.2015.214","article-title":"Modulation of protein-protein interactions for the development of novel therapeutics","volume":"24","author":"Petta","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.drudis.2026.104728_b0115","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1002\/anie.200200558","article-title":"Modulation of protein-protein interactions with small organic molecules","volume":"42","author":"Berg","year":"2003","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.drudis.2026.104728_b0120","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1016\/j.bmcl.2014.03.095","article-title":"Hot spot-based design of small-molecule inhibitors for protein-protein interactions","volume":"24","author":"Guo","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104728_b0125","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2026.104728_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112400","article-title":"Negative regulator IL-1 receptor 2 (IL-1R2) and its roles in immune regulation of autoimmune diseases","volume":"136","author":"Zhang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.drudis.2026.104728_b0135","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nsmb.2260","article-title":"Structure of the activating IL-1 receptor signaling complex","volume":"19","author":"Thomas","year":"2012","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.drudis.2026.104728_b0140","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1073\/pnas.1217996110","article-title":"Design of a superior cytokine antagonist for topical ophthalmic use","volume":"110","author":"Hou","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2026.104728_b0145","doi-asserted-by":"crossref","first-page":"36927","DOI":"10.1074\/jbc.M006071200","article-title":"X-ray crystal structure of a small antagonist peptide bound to interleukin-1 receptor type 1","volume":"275","author":"Vigers","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2026.104728_b0150","article-title":"Identification of potential small molecule allosteric modulator sites on IL-1R1 ectodomain using accelerated conformational sampling method","volume":"10","author":"Yang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2026.104728_b0155","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3390\/ijms19071835","article-title":"DPIE [2-(1,2-diphenyl-1H-indol-3-yl)ethanamine] augments pro-inflammatory cytokine production in IL-1\u03b2-stimulated primary human oral cells","volume":"19","author":"Ahn","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104728_b0160","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/intimm\/13.12.1533","article-title":"Adenosine regulates the IL-1 beta-induced cellular functions of human gingival fibroblasts","volume":"13","author":"Murakami","year":"2001","journal-title":"Int Immunol"},{"key":"10.1016\/j.drudis.2026.104728_b0165","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3390\/molecules27030899","article-title":"Synthesis of DPIE [2-(1,2-diphenyl-1H-indol-3-yl)ethanamine] derivatives and their regulatory effects on pro-inflammatory cytokine production in IL-1\u03b2-stimulated primary human oral cells","volume":"27","author":"Lim","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2026.104728_b0170","article-title":"5-Fluoro\/(trifluoromethoxy)-2-indolinone derivatives with anti-interleukin-1 activity","volume":"356","author":"Soylu-Eter","year":"2023","journal-title":"Arch Pharm (Weinh)"},{"key":"10.1016\/j.drudis.2026.104728_b0175","doi-asserted-by":"crossref","first-page":"8141","DOI":"10.1021\/acs.jmedchem.4c00240","article-title":"Ligandability assessment of IL-1\u03b2 by integrated hit identification approaches","volume":"67","author":"Vulpetti","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104728_b0180","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/ni.3370","article-title":"Interleukin 33 is a guardian of barriers and a local alarmin","volume":"17","author":"Martin","year":"2016","journal-title":"Nat Immunol"},{"key":"10.1016\/j.drudis.2026.104728_b0185","doi-asserted-by":"crossref","first-page":"14918","DOI":"10.1073\/pnas.1308651110","article-title":"Structural insights into the interaction of IL-33 with its receptors","volume":"110","author":"Liu","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2026.104728_b0190","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1158\/0008-5472.CAN-13-2797","article-title":"BCR-ABL-induced deregulation of the IL-33\/ST2 pathway in CD34+ progenitors from chronic myeloid leukemia patients","volume":"74","author":"Levescot","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2026.104728_b0195","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/1062936X.2020.1837239","article-title":"Structure-based discovery of interleukin-33 inhibitors: a pharmacophore modelling, molecular docking, and molecular dynamics simulation approach","volume":"31","author":"Le","year":"2020","journal-title":"SAR QSAR Environ Res"},{"key":"10.1016\/j.drudis.2026.104728_b0200","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1002\/asia.202100896","article-title":"Rational design, synthesis and evaluation of oxazolo[4,5-c]-quinolinone analogs as novel interleukin-33 inhibitors","volume":"16","author":"Kim","year":"2021","journal-title":"Chem Asian J"},{"key":"10.1016\/j.drudis.2026.104728_b0205","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1007\/s11030-021-10359-4","article-title":"Discovery of small molecular inhibitors for interleukin-33\/ST2 protein-protein interaction: a virtual screening, molecular dynamics simulations and binding free energy calculations","volume":"26","author":"Mai","year":"2022","journal-title":"Mol Divers"},{"key":"10.1016\/j.drudis.2026.104728_b0210","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99208","article-title":"From proteomics to discovery of first-in-class ST2 inhibitors active in vivo","volume":"3","author":"Ramadan","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.drudis.2026.104728_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116942","article-title":"Structure-activity relationship of 1-(furan-2ylmethyl)pyrrolidine-based stimulation-2 (ST2) inhibitors for treating graft versus host disease","volume":"71","author":"Yuan","year":"2022","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2026.104728_b0220","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1021\/acsptsci.3c00122","article-title":"Prophylactic mitigation of acute graft versus host disease by novel 2-(pyrrolidin-1-ylmethyl)pyrrole-based stimulation-2 (ST2) inhibitors","volume":"6","author":"Yuan","year":"2023","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.drudis.2026.104728_b0225","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1021\/acsmedchemlett.4c00459","article-title":"Studies of structure-activity relationship of 2-(pyrrolidin-1ylmethyl)-1H-pyrrole-based ST2 inhibitors and their inhibition of mast cells activation","volume":"15","author":"Yuan","year":"2024","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104728_b0230","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.immuni.2010.08.004","article-title":"Interleukin-2 receptor signaling: at the interface between tolerance and immunity","volume":"33","author":"Malek","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.drudis.2026.104728_b0235","doi-asserted-by":"crossref","first-page":"6440","DOI":"10.1038\/s41467-020-20220-1","article-title":"An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer","volume":"11","author":"Sahin","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104728_b0240","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1126\/science.1109745","article-title":"The structure of interleukin-2 complexed with its alpha receptor","volume":"308","author":"Rickert","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104728_b0245","doi-asserted-by":"crossref","first-page":"7589","DOI":"10.1021\/ja970702x","article-title":"Identification of a small molecule inhibitor of the IL-2\/IL-2R\u03b1 receptor interaction which binds to IL-2","volume":"119","author":"Tilley","year":"1997","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drudis.2026.104728_b0250","doi-asserted-by":"crossref","first-page":"6475","DOI":"10.1021\/bi034138g","article-title":"Discovery and characterization of cooperative ligand binding in the adaptive region of interleukin-2","volume":"42","author":"Hyde","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2026.104728_b0255","doi-asserted-by":"crossref","first-page":"15280","DOI":"10.1021\/ja0382617","article-title":"Potent small-molecule binding to a dynamic hot spot on IL-2","volume":"125","author":"Thanos","year":"2003","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drudis.2026.104728_b0260","doi-asserted-by":"crossref","first-page":"11420","DOI":"10.1021\/acs.jmedchem.0c00242","article-title":"Fragment linking strategies for structure-based drug design","volume":"63","author":"Bancet","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104728_b0265","doi-asserted-by":"crossref","first-page":"17496","DOI":"10.1021\/acs.jmedchem.1c01693","article-title":"Identification and validation of new interleukin-2 ligands using DNA-encoded libraries","volume":"64","author":"Gironda-Mart\u00ednez","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104728_b0270","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nri1901","article-title":"The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design","volume":"6","author":"Waldmann","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drudis.2026.104728_b0275","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4049\/jimmunol.167.1.277","article-title":"The sushi domain of soluble IL-15 receptor alpha is essential for binding IL-15 and inhibiting inflammatory and allogenic responses in vitro and in vivo","volume":"167","author":"Wei","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2026.104728_b0280","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/ni1492","article-title":"Crystal structure of the IL-15-IL-15Ralpha complex, a cytokine-receptor unit presented in trans","volume":"8","author":"Chirifu","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.drudis.2026.104728_b0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph7010001","article-title":"A new phenylpyrazoleanilide, Y-320, inhibits interleukin 17 production and ameliorates collagen-induced arthritis in mice and cynomolgus monkeys","volume":"7","author":"Ushio","year":"2014","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.drudis.2026.104728_b0290","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ejmech.2017.05.034","article-title":"Pharmacophore guided discovery of small-molecule interleukin 15 inhibitors","volume":"136","author":"\u017by\u017cy\u0144ska-Granica","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104728_b0295","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.3390\/molecules28052287","article-title":"New, low-molecular weight chemical compounds inhibiting biological activity of interleukin 15","volume":"28","author":"Krzeczy\u0144ski","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2026.104728_b0300","article-title":"Systemic delivery of small interfering RNA targeting the interleukin-2\/15 receptor \u03b2 chain prevents disease progression in experimental arthritis","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2026.104728_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116161","article-title":"Rational modification, synthesis and biological evaluation of N-substituted phthalazinone derivatives designed to target interleukine-15 protein","volume":"39","author":"Smadja","year":"2021","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2026.104728_b0310","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S1470-2045(14)70319-5","article-title":"Siltuximab for multicentric Castleman\u2019s disease: a randomised, double-blind, placebo-controlled trial","volume":"15","author":"Van Rhee","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2026.104728_b0315","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1021\/jm401144z","article-title":"Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6\/GP130 interface","volume":"57","author":"Li","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104728_b0320","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1007\/s11030-022-10558-7","article-title":"Identification of small molecules as potential inhibitors of interleukin 6: a multi-computational investigation","volume":"27","author":"Tran","year":"2023","journal-title":"Mol Divers"},{"key":"10.1016\/j.drudis.2026.104728_b0325","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jaci.2007.03.018","article-title":"3-O-Formyl-20R,21-epoxyresibufogenin suppresses IL-6-type cytokine actions by targeting the glycoprotein 130 subunit: potential clinical implications","volume":"120","author":"Kino","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2026.104728_b0330","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3390\/molecules28020677","article-title":"Carbohydrate-small molecule hybrids as lead compounds targeting IL-6 signaling","volume":"28","author":"Schultz","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2026.104728_b0335","doi-asserted-by":"crossref","first-page":"7082","DOI":"10.1021\/jf100421w","article-title":"Chrysin suppresses IL-6-induced angiogenesis via down-regulation of JAK1\/STAT3 and VEGF: an in vitro and in ovo approach","volume":"58","author":"Lin","year":"2010","journal-title":"J Agric Food Chem"},{"key":"10.1016\/j.drudis.2026.104728_b0340","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104728_b0345","doi-asserted-by":"crossref","first-page":"8354","DOI":"10.1021\/acs.jmedchem.1c00327","article-title":"Macrolide inspired macrocycles as modulators of the IL-17A\/IL-17RA interaction","volume":"64","author":"Ko\u0161trun","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104728_b0350","article-title":"Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists","volume":"6","author":"Liu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104728_b0355","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1021\/acsmedchemlett.2c00257","article-title":"Multicomponent macrocyclic IL-17a modifier","volume":"13","author":"Abdelraheem","year":"2022","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104728_b0360","doi-asserted-by":"crossref","first-page":"16692","DOI":"10.1021\/acs.jmedchem.4c01520","article-title":"Discovery and in vivo exploration of 1,3,4-oxadiazole and \u03b1-fluoroacrylate containing IL-17 inhibitors","volume":"67","author":"Velcicky","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104728_b0365","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202400851","article-title":"Thiazole-based IL-17 inhibitors discovered by scaffold morphing","volume":"20","author":"Velcicky","year":"2025","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drudis.2026.104728_b0370","doi-asserted-by":"crossref","first-page":"8828","DOI":"10.1021\/acs.jmedchem.2c00422","article-title":"Discovery of an oral, rule of 5 compliant, interleukin 17A protein-protein interaction modulator for the potential treatment of psoriasis and other inflammatory diseases","volume":"65","author":"Andrews","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104728_b0375","doi-asserted-by":"crossref","first-page":"26071","DOI":"10.1038\/srep26071","article-title":"Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide","volume":"6","author":"Liu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104728_b0380","doi-asserted-by":"crossref","first-page":"14561","DOI":"10.1038\/s41598-022-18760-1","article-title":"Identification and structure-based drug design of cell-active inhibitors of interleukin 17A at a novel C-terminal site","volume":"12","author":"Goedken","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104728_b0385","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nrd.2016.29","article-title":"Small molecules, big targets: drug discovery faces the protein-protein interaction challenge","volume":"15","author":"Scott","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104728_b0390","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/978-981-13-8719-7_13","article-title":"Allosteric modulators of protein-protein interactions (PPIs)","volume":"1163","author":"Ni","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.drudis.2026.104728_b0395","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41392-020-0107-0","article-title":"The role of ubiquitination in tumorigenesis and targeted drug discovery","volume":"5","author":"Deng","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2026.104728_b0400","doi-asserted-by":"crossref","DOI":"10.1126\/science.adf6249","article-title":"Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras","volume":"382","author":"Ahn","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104728_b0405","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41586-024-07947-3","article-title":"Transferrin receptor targeting chimeras for membrane protein degradation","volume":"638","author":"Zhang","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104728_b0410","doi-asserted-by":"crossref","first-page":"32933","DOI":"10.1021\/jacs.4c06160","article-title":"Conditionally activatable chimeras for tumor-specific membrane protein degradation","volume":"146","author":"Liu","year":"2024","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drudis.2026.104728_b0415","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41586-020-2760-4","article-title":"Structural basis for the action of the drug trametinib at KSR-bound MEK","volume":"588","author":"Khan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104728_b0420","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cell.2019.05.028","article-title":"A small molecule targeting mutagenic translesion synthesis improves chemotherapy","volume":"178","author":"Wojtaszek","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2026.104728_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102227","article-title":"Turning tumors from cold to inflamed to improve immunotherapy response","volume":"101","author":"Gerard","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.drudis.2026.104728_b0430","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41551-020-0549-2","article-title":"Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours","volume":"4","author":"Mansurov","year":"2020","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.drudis.2026.104728_b0435","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases","volume":"42","author":"Zhao","year":"2024","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2026.104728_b0440","doi-asserted-by":"crossref","first-page":"31780","DOI":"10.1073\/pnas.2013615117","article-title":"An engineered 4-1BBL fusion protein with \u201cactivity on demand\u201d","volume":"117","author":"Mock","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2026.104728_b0445","doi-asserted-by":"crossref","DOI":"10.1126\/science.adn0327","article-title":"Hematopoietic aging promotes cancer by fueling IL-1\u237a-driven emergency myelopoiesis","volume":"386","author":"Park","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104728_b0450","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.immuni.2024.11.008","article-title":"Elevated IL-22 as a result of stress-induced gut leakage suppresses septal neuron activation to ameliorate anxiety-like behavior","volume":"58","author":"Xia","year":"2025","journal-title":"Immunity"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:44:19Z","timestamp":1789505059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626001339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":90,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1359644626001339"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104728","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From biologics to small-molecule modulators: the evolving landscape of interleukin-targeted therapeutics","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104728","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104728"}}